Q-omics provides the consensus-scored RARRES2P1 profile across patient tissues and cancer cell-line models. RARRES2P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RARRES2P1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, RARRES2P1 RNA expression shows 14,474 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where RARRES2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RARRES2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RARRES2P1 survival associations across molecular data types. RARRES2P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RARRES2P1 RNA expression–survival associations across cancer types. High RARRES2P1 expression shows unfavorable associations in KIRC, SKCM, LUAD and MESO, but favorable associations in KIRP and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RARRES2P1 RNA expression.
This table summarizes RARRES2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RARRES2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RARRES2P1 shows lower tumor expression in KICH, KIRC, BRCA and THCA and higher tumor expression in LUAD and CHOL. The KICH box plot shows higher RARRES2P1 RNA expression in normal versus tumor tissue (log2 FC = −1.020, t-test p < 0.001).
This table shows molecular features associated with RARRES2P1 in patient tissues and cancer cell lines. In patient samples, RARRES2P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
